Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 503

1.

Pathogenic contribution of the Macrophage migration inhibitory factor family to major depressive disorder and emerging tailored therapeutic approaches.

Petralia MC, Mazzon E, Fagone P, Basile MS, Lenzo V, Quattropani MC, Bendtzen K, Nicoletti F.

J Affect Disord. 2020 Feb 15;263:15-24. doi: 10.1016/j.jad.2019.11.127. Epub 2019 Nov 30. Review.

2.

Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke.

Enevold C, Nielsen CH, Molbo D, Lund R, Bendtzen K, Fiehn N-, Holmstrup P.

Sci Rep. 2019 Apr 18;9(1):6283. doi: 10.1038/s41598-019-42594-z.

3.

Pattern recognition receptor polymorphisms in early periodontitis.

Leite FRM, Enevold C, Bendtzen K, Baelum V, López R.

J Periodontol. 2019 Jun;90(6):647-654. doi: 10.1002/JPER.18-0547. Epub 2018 Dec 19.

PMID:
30517775
4.

Gasotransmitters and the immune system: Mode of action and novel therapeutic targets.

Fagone P, Mazzon E, Bramanti P, Bendtzen K, Nicoletti F.

Eur J Pharmacol. 2018 Sep 5;834:92-102. doi: 10.1016/j.ejphar.2018.07.026. Epub 2018 Jul 20. Review.

PMID:
30016662
5.

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.

Prado MS, Bendtzen K, Andrade LEC.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):985-995. doi: 10.1080/17425255.2017.1360280. Epub 2017 Aug 14. Review.

PMID:
28772079
6.

Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium Porphyromonas gingivalis.

Køllgaard T, Enevold C, Bendtzen K, Hansen PR, Givskov M, Holmstrup P, Nielsen CH.

PLoS One. 2017 Feb 24;12(2):e0172773. doi: 10.1371/journal.pone.0172773. eCollection 2017.

7.

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Bendtzen K, Steenholdt C.

Aliment Pharmacol Ther. 2017 Mar;45(5):759-760. doi: 10.1111/apt.13921. No abstract available.

8.

HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?

Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S, Nicoletti F.

Int J Cancer. 2017 Apr 15;140(8):1713-1726. doi: 10.1002/ijc.30529. Epub 2017 Jan 20. Review.

9.

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.

Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M.

PLoS One. 2016 Sep 8;11(9):e0162316. doi: 10.1371/journal.pone.0162316. eCollection 2016.

10.

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.

Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA.

Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015. doi: 10.1097/MIB.0000000000000772. Review.

PMID:
27135483
11.

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.

Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, Nielsen OH.

Medicine (Baltimore). 2016 Apr;95(16):e3417. doi: 10.1097/MD.0000000000003417.

12.

Monitoring immunogenicity of protein-based TNF antagonists.

Bendtzen K, Steenholdt C, Brynskov J, Thomsen OØ, Ainsworth MA.

Frontline Gastroenterol. 2016 Apr;7(2):152-154. doi: 10.1136/flgastro-2015-100596. Epub 2015 May 14. No abstract available.

13.

Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro.

Hansen JF, Brorson MM, Boas M, Frederiksen H, Nielsen CH, Lindström ES, Hofman-Bang J, Hartoft-Nielsen ML, Frisch T, Main KM, Bendtzen K, Rasmussen ÅK, Feldt-Rasmussen U.

PLoS One. 2016 Mar 17;11(3):e0151192. doi: 10.1371/journal.pone.0151192. eCollection 2016.

14.

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.

Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OØ, Brynskov J.

J Clin Gastroenterol. 2016 Jul;50(6):483-9. doi: 10.1097/MCG.0000000000000375.

PMID:
26166141
15.

Influence of phthalates on in vitro innate and adaptive immune responses.

Hansen JF, Nielsen CH, Brorson MM, Frederiksen H, Hartoft-Nielsen ML, Rasmussen ÅK, Bendtzen K, Feldt-Rasmussen U.

PLoS One. 2015 Jun 25;10(6):e0131168. doi: 10.1371/journal.pone.0131168. eCollection 2015.

16.

Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence.

Bendtzen K.

Front Immunol. 2015 Apr 8;6:152. doi: 10.3389/fimmu.2015.00152. eCollection 2015. Review.

17.

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection.

Bendtzen K.

Front Immunol. 2015 Apr 8;6:109. doi: 10.3389/fimmu.2015.00109. eCollection 2015. Review.

18.

Influence of phthalates on cytokine production in monocytes and macrophages: a systematic review of experimental trials.

Hansen JF, Bendtzen K, Boas M, Frederiksen H, Nielsen CH, Rasmussen ÅK, Feldt-Rasmussen U.

PLoS One. 2015 Mar 26;10(3):e0120083. doi: 10.1371/journal.pone.0120083. eCollection 2015. Review.

19.

Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study.

Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, Lindegaard HM, Omerovic E, Højgaard P, Jensen EK, Bouchelouche PN.

Arthritis. 2015;2015:784825. doi: 10.1155/2015/784825. Epub 2015 Feb 11.

20.

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.

PMID:
25673037
21.

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.

J Crohns Colitis. 2015 Mar;9(3):238-45. doi: 10.1093/ecco-jcc/jjv004. Epub 2015 Jan 9.

PMID:
25576753
22.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA.

BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

23.

Effect of melatonin on human nighttime endotoxaemia: randomized, double-blinded, cross-over study.

Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I.

In Vivo. 2014 Nov-Dec;28(6):1057-63.

PMID:
25398799
24.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
26.

Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus.

Enevold C, Nielsen CH, Jacobsen RS, Hermansen ML, Molbo D, Avlund K, Bendtzen K, Jacobsen S.

Mol Biol Rep. 2014 Sep;41(9):5755-63. doi: 10.1007/s11033-014-3447-4. Epub 2014 Jun 12.

PMID:
24919757
27.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Am J Gastroenterol. 2014 Jul;109(7):1055-64. doi: 10.1038/ajg.2014.106. Epub 2014 May 6.

PMID:
24796769
28.

Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers.

Halladin NL, Ekeløf S, Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I.

Perfusion. 2015 Jan;30(1):64-70. doi: 10.1177/0267659114530769. Epub 2014 Apr 10.

PMID:
24722849
29.

Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes.

Enevold C, Kjær L, Nielsen CH, Voss A, Jacobsen RS, Hermansen ML, Redder L, Oturai AB, Jensen PE, Bendtzen K, Jacobsen S.

Rheumatol Int. 2014 Oct;34(10):1401-8. doi: 10.1007/s00296-014-3012-4. Epub 2014 Apr 10.

PMID:
24719229
30.

Hypomethylating agent 5-aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models.

Mangano K, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, Di Rosa M, Malaguarnera L, Coco M, Magro G, Di Marco R, Nicoletti F.

J Cell Physiol. 2014 Dec;229(12):1918-25. doi: 10.1002/jcp.24641.

PMID:
24700487
31.

Pronounced inflammatory response to endotoxaemia during nighttime: a randomised cross-over trial.

Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I.

PLoS One. 2014 Jan 27;9(1):e87413. doi: 10.1371/journal.pone.0087413. eCollection 2014.

32.

Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model.

Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I.

J Crit Care. 2014 Feb;29(1):184.e9-184.e13. doi: 10.1016/j.jcrc.2013.09.006. Epub 2013 Oct 17.

PMID:
24140166
33.

Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' reply.

Nielsen CH, Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B.

Aliment Pharmacol Ther. 2013 Sep;38(5):552-3. doi: 10.1111/apt.12426. No abstract available.

34.

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.

PMID:
23878167
35.

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K.

Ther Drug Monit. 2013 Aug;35(4):530-8. doi: 10.1097/FTD.0b013e31828d23c3.

PMID:
23765033
36.

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.

Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH.

Aliment Pharmacol Ther. 2013 Jun;37(12):1172-83. doi: 10.1111/apt.12330. Epub 2013 May 7.

38.

Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.

Bendtzen K.

Immunotherapy. 2012 Nov;4(11):1167-79. doi: 10.2217/imt.12.114. Review.

PMID:
23194366
39.

Immunoregulation by naturally occurring and disease-associated autoantibodies : binding to cytokines and their role in regulation of T-cell responses.

Nielsen CH, Bendtzen K.

Adv Exp Med Biol. 2012;750:116-32. doi: 10.1007/978-1-4614-3461-0_9. Review.

PMID:
22903670
40.

Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.

Meyer MW, Zachariae C, Bendtzen K, Skov L.

Acta Derm Venereol. 2012 Jul;92(4):362-4. doi: 10.2340/00015555-1376. No abstract available.

41.

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.

Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K.

Aliment Pharmacol Ther. 2012 Oct;36(7):650-9. doi: 10.1111/apt.12010. Epub 2012 Aug 5.

42.

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD.

Steenholdt C, Brynskov J, Bendtzen K.

Aliment Pharmacol Ther. 2012 Sep;36(5):499-500; author reply 501. doi: 10.1111/j.1365-2036.2012.05204.x. No abstract available.

43.

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.

Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA.

Inflamm Bowel Dis. 2012 Dec;18(12):2209-17. doi: 10.1002/ibd.22910. Epub 2012 Feb 16.

PMID:
22344964
44.

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA.

J Crohns Colitis. 2012 Feb;6(1):108-11. doi: 10.1016/j.crohns.2011.08.001. Epub 2011 Aug 31.

PMID:
22261535
45.

[Danger signals and inflammasomes in autoinflammatory and autoimmune diseases].

Bendtzen K.

Ugeskr Laeger. 2011 Sep 19;173(38):2340-3. Danish.

PMID:
21936977
46.

[Innate immunity, autoimmunity and autoinflammation].

Bendtzen K.

Ugeskr Laeger. 2011 Sep 19;173(38):2337-40. Danish.

PMID:
21936976
47.

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists.

Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, Blanchard B, Lebon P, Taylor P, Charles P, Alzabin S, Tovey MG.

J Immunol Methods. 2011 Oct 28;373(1-2):229-39. doi: 10.1016/j.jim.2011.08.022. Epub 2011 Sep 3.

PMID:
21910993
48.

Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatin.

Vindeløv SD, Hartoft-Nielsen ML, Rasmussen ÅK, Bendtzen K, Kosteljanetz M, Andersson AM, Feldt-Rasmussen U.

Growth Horm IGF Res. 2011 Jun;21(3):134-9. doi: 10.1016/j.ghir.2011.03.005.

PMID:
21658592
49.

Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis.

Hedegaard CJ, Enevold C, Sellebjerg F, Bendtzen K, Nielsen CH.

PLoS One. 2011;6(5):e20253. doi: 10.1371/journal.pone.0020253. Epub 2011 May 20.

50.

mTOR as a multifunctional therapeutic target in HIV infection.

Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K.

Drug Discov Today. 2011 Aug;16(15-16):715-21. doi: 10.1016/j.drudis.2011.05.008. Epub 2011 May 23.

Supplemental Content

Loading ...
Support Center